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Paclitaxel-loaded phosphonated 
calixarene nanovesicles as a 
modular drug delivery platform
Jingxin Mo1,2, Paul K. Eggers3, Zhi-xiang Yuan4, Colin L. Raston5 & Lee Yong Lim1
A modular p-phosphonated calix[4]arene vesicle (PCV) loaded with paclitaxel (PTX) and conjugated 
with folic acid as a cancer targeting ligand has been prepared using a thin film-sonication method. It 
has a pH-responsive capacity to trigger the release of the encapsulated PTX payload under mildly acidic 
conditions. PTX-loaded PCV conjugated with alkyne-modified PEG-folic acid ligands prepared via click 
ligation (fP-PCVPTX) has enhanced potency against folate receptor (FR)-positive SKOV-3 ovarian tumour 
cells over FR-negative A549 lung tumour cells. Moreover, fP-PCVPTX is also four times more potent 
than the non-targeting PCVPTX platform towards SKOV-3 cells. Overall, as a delivery platform the PCVs 
have the potential to enhance efficacy of anticancer drugs by targeting a chemotherapeutic payload 
specifically to tumours and triggering the release of the encapsulated drug in the vicinity of cancer cells.
The ability to direct a drug payload specifically and solely to a particular cellular type is regarded as a Holy Grail 
in chemotherapy. Most current chemotherapeutic agents are highly efficacious, but they are also associated with 
debilitating toxicity, essentially due to their indiscriminate attack on both cancerous and rapidly dividing healthy 
cells. To improve treatment outcomes, several targeting drug delivery approaches have been devised with various 
degrees of success. One approach is to design pH-sensitive polymeric platforms to trigger the release of a drug 
payload upon extravasation into cancer tissues, the optimal system being capable of responding with adequate 
discrimination to the small pH difference between blood and tumour milieu (pH 7.4 vs. pH 5.5)1–3. Another 
approach is to target receptors that are overly expressed on cancer cell membranes, in particular the folate 
receptor (FR) which has been the target of choice for a diverse range of delivery platforms, including pegylated 
micelles4–6, vesicles modified with acid-triggered drug releasing mechanisms7 and derivatised liposomes8. The 
basis for this approach stems from the essential role that folic acid (FA) plays in cell division and DNA synthe-
sis, and the significant upregulation of FR in a number of epithelial cancers, e.g. ovarian tumours9, to meet the 
increased demand for FA during cell proliferation. Binding of FA to the membrane FR initiates FA internalization 
as well as any drug delivery platform strategically conjugated to the FA. Subsequent sequestration of the contents 
into acidic endosomes ensures that the approach does not only result in cancer-directed drug delivery, but has the 
potential to also enhance cellular uptake of the delivered drug. This coupled with the low to absent FR expression 
on normal cells10, and FA being a relatively cheap and commercially available small molecule that is amendable to 
chemical modification without losing its FR binding efficiency11, has made the FR-targeting approach a popular 
route for directing chemotherapeutics into tumours12.
This paper describes an extension of our work on calix[4]arene-based phospholipid mimic vesicles (PCV) by 
incorporating the above two cancer targeting strategies to direct the delivery of the potent but toxic drug, pacl-
itaxel (PTX), to ovarian cancer cells. We have previously shown such calix[4]arenes are non-toxic13 and potent 
anti-oxidants14 with innate capacity to assemble into micelles and vesicles in aqueous media. The resultant vesicles 
can be wrapped with polymers for increased stability15, tagged with fluorescent molecules for tracking15, inter-
calated with non-polar drugs14, as well as hosting a polar carboplatin molecule in its molecular cavity16. In the 
present work we demonstrate a facile click-based method to modularly functionalize the PCV surface with long 
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chain polyethylene glycol (PEG) and folic acid to provide a targeted delivery system for PTX. PTX is a widely 
used potent chemotherapeutic agent with intractable water insolubility and significant dose-limiting cardiotoxic-
ity17–20. A liposomal PTX formulation has been developed to resolve the solubility issues and has recently become 
available to clinicians21. Compared to the cremophor-based paclitaxel formulation, this novel formulation has a 
better safety profile21. However, this formulation has no built-in active targeting capacity and thus exhibits similar 
antitumor effects22. We are endeavouring to develop a robust delivery platform that can be readily modified to 
incorporate targeting and pH-triggered drug release capabilities to improve the therapeutic index of PTX, and 
by extension, any other potent chemotherapeutic payload. Indeed, as described herein, the proof-of-concept 
PTX-loaded folate-PEG PCV exhibits significantly enhanced drug efficacy and discriminated with high selectiv-
ity towards cell lines with increased FR expression.
Results and Discussion
Design and Synthesis of the Calixarenes. The calix[4]arene based phospholipid mimic described herein 
(Fig. 1) is amphiphilic with polar phosphonate/phosphonic acid “head” groups and non-polar aliphatic “tails”. 
This structure mimics phospholipids which make up the membrane of animal cells with the exception that the 
calix[4]arene forms a rigid “cup” or scaffold where the four head groups are constrained to point in one direction, 
with the alkyl chain “tails” in the other. This construct lends itself to be able to replace one of the four phosphonate 
head groups in the molecule P4C6 with an azide “linker” group as the molecule P3C6N3, without significantly 
disrupting the structural stability of the ensuing self assembled vesicles when P3C6N3 is mixed with P4C6. The 
azide linker enables modification of the surface of the vesicles with targeting ligands and/or imaging moieties 
through “Click” chemistry. Such chemistry can be performed under biologically relevant conditions, and has fast 
kinetics with high chemo- and regio-specificity, forming a single reaction product in high yield23. We have found 
that tethering the targeting ligands to the vesicle surface can be achieved under mild reaction conditions within 
the vesicle forming media which is deemed necessary to preserve both the integrity of the sensitive targeting 
molecules24 and the stability of the vesicles.
The synthesis of P4C6 has been described previously16 and the synthesis of P3C6N3 was accomplished via 
modifying a method described for the synthesis of the corresponding n-dodecyl substituted calixarenes, rather 
than the n-hexyl in the present study15. As described in detail in the ESI, this included standard calix[4]arene 
synthesis followed by addition of the n-hexyl groups through bromohexane and sodium hydride in DMF, formyl-
ation via the Duff reaction, reduction to the alcohol with sodium borohydride, chlorination with thionyl chloride, 
phosphorylation with triethylphosphite in a three to one calix[4]arene ratio, deprotection using bromotrimethyl-
silane followed by reaction with sodium azide to form the final compound, P3C6N3.
Figure 1. Click-based modular drop-in strategy for the preparation of PTX-loaded, folate-PEG P4C6 
vesicles (fP-PCVPTX). 
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Fabrication of the Phosphonated Calix[4]arene Vesicles. Phosphonated calix[4]arene vesicles (PCV) 
were prepared by mixing P4C6 with P3C6N3 (1 mol % relative to P4C6) using the thin-film method25. The hydro-
dynamic diameter (DH) of the PCVs was 112 ± 8 nm as measured by dynamic light scattering, and the zeta poten-
tial (ζ ) was − 38.76 ± 3.94 mV at pH 7.0, 25 °C, indicating a high degree of stability in aqueous media.
Paclitaxel Loading and Release. PTX-loaded phosphonated calix[4]arene vesicles (PCVPTX) were 
prepared using the thin-film method25 with a PCV:PTX molar ratio of 4:1. Loading efficiency and encap-
sulation efficiency of PTX were 4.03 ± 0.42% and 90.21 ± 4.84% (W/W, n = 3), respectively. The PCVPTX had 
DH = 139 ± 16 nm, which was larger than the blank PCV, and ζ = − 40.8 ± 5.87 mV at pH 7.0, 25 °C (Fig. 2), 
indicating that the PTX loading did not disrupt the PCV stability.
The drug release kinetics for PCVPTX (Fig. 3) were monitored at both normal tissue pH (pH 7.426) and cancer 
tissue pH (pH 5.526) using the previously described LC-TOF/MS assay method for PTX25. As anticipated from 
zeta potential measurements, PCVPTX demonstrated a degree of stability at the normal tissue pH of 7.4, with only 
20% of the PTX load released after 48 h at 37 °C. However, at the cancer tissue pH of 5.5 at 37 °C, 75% of the PTX 
load was released after 24 h, and 85% after 48 h. As eluded to previously, the enhanced drug releasing capacity 
of the PCV platform under acidic conditions compared to slightly basic conditions appears to be related to the 
first pKa of 7.2 for the phosphonic acid head groups27. At pH 7.4 the majority of phosphonic acid-head groups 
are expected to be singly deprotonated with a negative charge, whereas at pH 5.5, the majority of head groups are 
expected to be fully protonated, with the neutral molecules having significantly greater hydrophobic character. 
The loss of charge and the accompanying hydrophobic character implies that the vesicles will be destabilized 
within an acidic aqueous environment relative to the mildly basic pH 7.4 medium. This is important for chemo-
therapy as the vesicles will have a greater stability in systemic circulation at pH 7.4, with potential for complete 
PTX release following extravasation and retention in tumorigenic tissues where the pH in the extracellular milieu 
and in cytoplasmic lysosomes can decrease to pH 5.5.
Figure 2. PTX-loaded p-phosphonated calix[4]arene vesicles (PCVPTX): (A) DLS of PCVPTX, Z-average size is 
139 ± 16 nm, and (B) TEM image, scale bar 200 nm (10 nm for inset).
Figure 3. Time-dependent PTX-release profiles of PTX-loaded p-phosphonated calix[4]arene vesicles 
(PCVPTX) at 37 °C, into pH 5.5 (diamond symbol) and pH 7.4 (square) phosphate buffer media. 
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Tethering of Folic Acid to the Vesicle Surface. As discussed in the introduction, folic acid (FA) was 
chosen as the cancer targeting moiety. Poly (ethylene glycol) was incorporated as a spacer between the FA and 
the vesicle surface to enhance aqueous solubility, optimise the targeting activity of the surface-attached FA, and 
increase the potential for prolongation of systemic half-life of the vesicle, thus allowing for multiple passes of the 
vesicle through the targeted tumour site28. As the level of P3C6N3-PEG-Folate incorporated into the PCVs was 
relatively low (0.73% of P4C6), the folate acid would not affect the paclitaxel release profile of fP-PCVPTX, and this 
has been confirmed by comparing the paclitaxel release profile of fP-PCVPTX to that of PCVPTX.
As shown in Fig. 1, the FA residue was incorporated by attaching an alkyne-PEG-folate reagent to the 
azide-functionalized PCVPTX using a ‘Click’ reaction. To establish the conditions for the click reaction, equi-
molar amounts of alkyne-PEG-folate reagent and P3C6N3 (azide-functionality incorporated in PCVPTX) were 
mixed in the presence of CuSO4 and sodium ascorbate (Fig. 4). FTIR, Fig. 5B, establishes that both the P3C6N3 
azide absorption at 2122 cm−1 and the alkyne-PEG-folate alkyne absorption at 3333 cm−1 largely disappear, with 
Figure 4. Model ‘click’ reaction between the alkyne-PEG-folate reagent and P3C6N3 in the calixarene 
vesicle. 1. P4C6, 2. P3C6N3, 3. Alkyne-PEG-folate, 4. P3C6N3-PEG-folate.
Figure 5. (A) Reverse-phase HPLC chromatogram of the crude click chemistry reaction mixture. (B) The FTIR 
spectra of the P3C6N3, Alkyne-PEG-Folate, and the click product. Peaks for azido and alkyne moieties were not 
apparent in the spectrum for the “click” product.
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the appearance of an absorption band at 3136 cm−1 which corresponds to a triazole. This establishes that the 
PEG-folate is tethered to calixarene molecules within the vesicle. It was not anticipated that the reaction would go 
beyond 50% as vesicles have an inner surface and an outer surface, and the mild conditions of the click reaction 
were expected to only modify the outer surface. Scrambling of calixarene molecules between the outer and inner 
layers of the vesicle bilayer is expected to require mechanical energy input, as in the use of the thin film vortex 
fluidic device for vesicles built of P4C816. However, HPLC of the deconstructed vesicle, Fig. 5A, established a 75% 
conversion of available triazide sites. The reaction was then repeated by treating the parent azide-functionalized 
PCVPTX with a lower 1 mol % (relative to P4C6 in the PCVs) of the alkyne-PEG-folate reagent, under similar 
conditions. The level of P3C6N3-PEG-Folate incorporated on the PCVs was kept below 1 mol % of P4C6, noting 
that ~0.5 mol % of folate per liposome is reported as an optimized value for targeting studies29. After the “click” 
reaction and purification, the resulting folate-modified PCVs (fP-PCVs) contained approximately 0.73 mol % of 
P3C6N3-PEG-Folate, as determined by UV–vis spectroscopy (Fig. S1 in Supporting Information).
Cellular Uptake of fP-PCVFITC. As described in the introduction, folate receptor (FR) mediated endocytosis 
has been shown to also mediate the cellular uptake of moieties attached to the folate molecule. Here we pro-
vide evidence that the attached folate assists fP-PCVFITC to undergo endocytosis by exposing FR-overexpressing 
SKOV-3 human ovarian carcinoma cells and FR-negative A549 human epithelial lung carcinoma cells to either 
PCVFITC, fP-PCVFITC or fP-PCVFITC with excess free folate. The CLSM images of all the incubated cells are shown 
in Fig. 6.
As shown in Fig. 6, the greatest FITC fluorescence was detected in the SKOV-3 cells exposed to fP-PCVFITC 
alone (Fig. 6B) compared to those incubated with PCVFITC (Fig. 6A), fP-PCVFITC with free folate (Fig. 6C) or 
any of the exposed A549 cells (Fig. 6D–F). The variation of intensity of fluorescent signals shown between the 
fluorescence experiments of Fig. 6 agrees with the expectation that folate assisted FR-mediated endocytosis will 
provide the mechanism to assist in the uptake of folate tagged fP-PCVFITC. For instance, Fig. 6A shows SKOV-3 
cells exposed to PCVFITC which lacks the folate tag and Fig. 6B shows SKOV-3 cells exposed to fP-PCVFITC, with 
the sharp decrease in fluorescence between Fig. 6A,B strongly indicates that the folate tag on the PCVs plays a 
significant role in the uptake of the FITC payload by the cells. This is further emphasised by the sharp decrease 
in fluorescence when a significant excess of free folate is added to the media prior to fP-PCVFITC being incubated 
with SKOV-3 cells (Fig. 6C). In this experiment the free folate binds to the FR of the SKOV-3 cells, and hence 
blocks the fP-PCVFITC from binding to the receptors. The significant drop in fluorescence gives further evidence 
that it is attachment of the folate to the PCVs that assists in the endocytosis of the PCVs.
As a control, A549 cells which lack the FR were incubated with the same samples as the SKOV-3 cells and in 
all cases the A549 cells showed very low fluorescence of approximately the same intensity. This indicates a similar 
but very low uptake of the PCVs, thereby providing further evidence that both the folate receptor and the folate 
tag on fP-PCVFITC are responsible for the strong fluorescence in Fig. 6B. This in turn supports our hypothesis that 
the internalization of fP-PCVFITC by the SKOV-3 cells is mediated by the folate receptor.
The incubated cells used in the fluorescence study described above were also analysed by flow cytometry. The 
gate of FITC was established using control groups of SKOV-3 cells and A549 cells, as shown in Fig. 7A,E. The 
quantitative flow cytometry data shown in Fig. 7 is consistent with the CLSM images of fluorescence in Fig. 6, 
indicating that fP-PCVFITC is actively internalized by SKOV-3 cells while PCVFITC is entering the SKOV-3 and 
A549 cells by non-specific adsorptive endocytosis. For instance, 16.6% of SKOV-3 cells are located in the FITC 
subset when incubated with PCVFITC (Fig. 7B) in comparison to 72.6% when incubated with the folate tagged 
fP-PCVFITC (Fig. 7C). This establishes a 337% increase in uptake when the targeting tag is used. Furthermore, the 
shape of the FITC intensity graph in Fig. 7B shows a gradual decrease in PCVFITC incubated cell numbers going 
into the FITC subset which implies a passive process of internalization, while the multi-peaks within the FITC 
subset of the fP-PCVFITC incubated cells (Fig. 7C) indicate process(es) other than passive permeation through 
the cell membrane. When the folate receptors were blocked by excess free folate (Fig. 7D), the cellular uptake of 
fP-PCVFITC dropped to 15.1%, which is similar to the level of untagged PCVFITC. This would appear to indicate 
that the passive permeation of the SKOV-3 cell membrane by both fP-PCVFITC and PCVFITC is around 15%, how-
ever, the small multipeak shown in Fig. 7D suggests that some of the fP-PCVFITC is internalised through some 
multivalent FR binding sites which are not accessible to the free folate. The flow cytometry FITC subset data for 
the A549 cells incubated with either PCVFITC, fP-PCVFITC or fP-PCVFITC including excess folate were between 
5–7% (Fig. 7F–H) and had a steady decrease of cell numbers in the FTIC subset. This indicates that only passive 
permeation of the cell membrane occurs without the folate receptors on the surface of the A549 cells.
PCV - Paclitaxel Efficacy. As mentioned in the introduction, PTX is an effective anti-cancer drug, however, 
it also kills normal cells that reproduce rapidly which results in serious side effects. A PTX delivery system that 
releases the drug primarily to cancer cells would lower side effects and improve the therapeutic outcomes. The 
fluorescent studies have shown that the folate tagged fP-PCVFITC increases the uptake of an intercalated dye by 
337% over the untagged PCV, while the in vitro dissolution studies have shown that in aqueous media with a 
similar pH to the cancer milieu, there is a higher rate of release of PTX than in aqueous media with a similar pH 
to blood. Next, we investigate how the folate tagged fP-PCVPTX affects the efficacy of intercalated PTX through 
in vitro cytotoxicity experiments.
The FR-positive SKOV-3 cells and FR-deficient A549 cells were exposed to PTX presented as either free PTX, 
PCVPTX, fP-PCVPTX or fP-PCVPTX with free folate. The incubation regimes involved either a pulsed exposure, 
where the cells were incubated with PTX for 4 h followed by 68 h incubation in drug-free media, or a continuous 
exposure, where the cells were incubated for 72 h in drug-containing media. Post-exposure, the number of viable 
cells was counted by flow cytometry and expressed as a percentage relative to drug-naïve control cells. From the 
cell viability-PTX concentration plots in Fig. 8A–D, the half-maximum inhibitory concentrations (IC50 values) 
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Figure 6. Confocal laser-scanning fluorescence microscopy images of SKOV-3 cells (A–C) and A549 cells 
(D–F) after 8 h incubation with PCVFITC (A,D), fP-PCVFITC (B,E), and fP-PCVFITC with 2 mM folate (C,F), and 
then dying with DAPI.
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were calculated and are shown in Table 1. The degrees of potentiation (DOP)30 were calculated using equation 1 
and are shown in Fig. 8E–G.
= ×DOP [IC (free drug)/IC (drug in carrier)] 100% (1)50 50
The DOP in Fig. 8E–G clearly show the relative potency of PCVPTX and fP-PCVPTX compared to free PTX. 
However, what is important for reducing the side effects is the difference in DOP between the targeted fP-PCVPTX 
and non-targeted PCVPTX. In SKOV-3 cells, short exposure to fP-PCVPTX (DOP = 157%) is 3.6 fold more likely 
to result in cell death than short exposure to PCVPTX (DOP = 44%), indicating the higher potency of PTX when 
it is delivered via a targeting delivery platform. The capacity of fP-PCVPTX to be specific in its delivery of the drug 
payload to the targeted cells can be evaluated by comparing the responses of the different cell types. For instance, 
DOP values show the fP-PCVPTX to be 5.5 times more likely to kill the SKOV-3 cells to which it is targeted than 
the A549 cells. Conversely, non-specific adsorptive endocytosis is the dominant mechanism for PCVPTX uptake 
as the FR-negative A549 cells show no measurable difference in cell viability responses to the two formulations.
As expected from the fluorescence study, the cytotoxicity of fP-PCVPTX against the SKOV-3 cells was reduced 
about two-fold in the presence of free folate (Table 1), but the competing folate was unable to completely block the 
enhanced cytotoxicity conferred by the targeting fP-PCVPTX over the non-targeting PCVPTX, as indicated by the 
different IC50 values. This enhanced potency of fP-PCVPTX against the SKOV-3 cells may result from multivalent 
Figure 7. FITC intensity analysed by flow cytometry of SKOV-3 cells (A–D) and A549 cells (E–H) after 8 h 
incubation with cell culture media (A,E), PCVFITC (B,F), fP-PCVFITC (C,G), and fP-PCVFITC with 2 mM folate 
(D,H). Exposure to PCVFITC (B) and fP-PCVFITC (C) led to 16.6% and 72.6%, respectively, of SKOV-3 cells to 
be located in the FITC subset, indicating a 337% increase in active cellular internalisation of the vesicles tagged 
with the targeting ligand. (I) Bar graph showing FITC uptake from various FITC-loaded vesicle formulations by 
the SKOV-3 and A549 cells. Statistical analysis was performed using One-way ANOVA test. Values of *P < 0.05 
was considered statistically significant.
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Figure 8. (A–F) Cytotoxicity profiles for various PTX formulations against FR-overexpressing SKOV-3 cells 
and FR-negative A549 cells. Short incubation regime 1: (A) A549, (B) SKOV-3 cells that were exposed to PTX 
formulations for 4 h followed by 68 h post-incubation in drug-free media. Long incubation regime 2: (C) A549, 
(D) SKOV-3 cells that were incubated with PTX formulations for 72 h. The PTX formulations contained free 
paclitaxel (PTX), PTX-encapsulated phosphonated calix[4]arene vesicles (PCVPTX), and PTX-encapsulated, 
folate-conjugated PCV (fP-PCVPTX) with or without free folate. Relative degrees of potentiation (DOP) of 
various PTX-loaded vesicle formulations compared to free PTX, calculated as [IC50(free drug)/IC50(drug in 
carrier) × 100] for each cell line following the pulsed (E) and continuous (F) incubation regime. (G) Bar graph 
showing the DOP of fP-PCVPTX for each cell type in short and long incubation regimes. Statistical analysis was 
performed using One-way ANOVA test. Values of *P < 0.05 was considered statistically significant.
www.nature.com/scientificreports/
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FR binding sites which are not accessible to the free folate31. Furthermore, this was not due to the cytotoxicity 
of the P4C6 as a 76-fold higher concentration of P4C6 alone (78 μM)16 was required to yield the same cytotoxic 
effect as PCVPTX against the SKOV-3 cells over 72 h.
Long incubation regimes highlight the reduction in difference of cytotoxicities between fP-PCVPTX and 
PCVPTX toward SKOV-3 cells due to sufficient internalization of non-targeted PCVPTX over the longer period 
(Fig. 8F). This is consistent with a mechanism where targeting can enhance drug efficacy as FR-negative A549 
cells show no measurable difference in cell viability responses toward fP-PCVPTX and PCVPTX, for both incubation 
regimes (Fig. 8E,F).
The above data suggests that the optimized therapeutic window for any drug formulation must be derived 
separately for each cell type depending on the target receptor expression. The exposure time of a specific cancer 
cell to multivalent receptor-targeted therapeutics such as fP-PCVPTX should be long enough to maximize effective 
receptor-mediated endocytosis but not so long as to have the uptake advantages being nullified by nonspecific 
processes. In this sense, it could be argued that our “click”-based drop-in strategy for the preparation of fP-PCVPTX 
may provide a facile and modular strategy for tuning the density and morphology of targeting moieties to match 
the spectrum of biological receptor expression on the cell surface to arrive at the optimum therapeutic window.
Summary. We have demonstrated a facile, modular strategy for the production of a targeted drug delivery 
system based on P4C6 vesicles. Our data show that these vesicles can effectively deliver a significant bolus of 
therapeutic agent to cancer cells. Once inside the cell, these vesicles can undergo triggered-release of the drug in 
cellular acidic microenvironments such as endosome. The incorporation of a terminal azide moiety into some 
of the amphiphilic molecules in the vesicles enables a modular, drop-in strategy for PCV functionalization, and 
allows for the conjugation of virtually any alkyne-modifiable targeting group onto PCVs without the loss of struc-
tural integrity or multivalent targeting capability. Coupled to the pronounced pH-sensitive release trigger of the 
P4C6 vesicles, the “clickable” PCV platform can facilitate the synthesis of a broad range of targeted therapeutics. 
As a proof of concept shown herein, folate-conjugated PCVs can be engineered to deliver drug payloads to spe-
cific receptor-positive tumour cells with high selectivity. The ability to engender stability, multivalent targeting 
capability, release trigger, and other functionalities into nanoscale drug delivery vehicles in a facile and modular 
fashion should make PCV a highly versatile platform that can significantly enhance the utility of nanoparticle 
delivery technology to tumours. Animal experiments will further be performed to evaluate the feasibility and 
safety of these strategies.
Methods
Materials. Unless otherwise noted, all reagents and materials were purchased from commercial sources and 
used as received. Dialysis bags were supplied by Spectrum Laboratories, Inc. (Rancho Dominguez, CA, cut off 
molecular weight of 3500 Da). Fluorescein isothiocyanate (FITC) and folic acid were purchased from Sigma-
Aldrich Corporation (St Louis, MO, USA). Phosphate buffered saline (PBS), fetal bovine serum (FBS) were supplied 
by Life Technologies (Carlsbad, CA, USA). Paclitaxel (purity > 99%) was purchased from Shanghai 21CEC Pharma 
(Shanghai, China). Ultrapure deionized water was obtained from a Millipore system (18.2 MΩ cm resistivity).
Measurements. Fourier-transformed nuclear magnetic resonance (NMR) spectroscopy was performed on 
a Varian 400 MHz spectrometer in the Centre for Microscopy, Characterisation and Analysis (CMCA) facilities. 
Chemical shifts of 1H NMR spectra are reported in ppm against residual solvent resonance as the internal stand-
ard (CHCl3 = 7.27 ppm, CHD2COCD3 = 2.05 ppm, CHD2OD = 3.31 ppm).
Fourier-transformed infrared (FTIR) spectroscopy was performed on a Perkin Elmer Spectrum One FTIR 
spectrometer. KBr-pellets were prepared for FTIR measurements of alkyne-PEG-folate, azide-modified PCV, 
and click products. UV− vis absorption spectra were obtained on a CARY 50 Bio UV− vis spectrophotometer. 
Confocal Laser Scanning Microscopy (CLSM) studies were performed on a Leica TCS SP2 multiphoton confocal 
microscope. UV/Visible Detector used here is Waters 2998 Diode Array Detector. The diode array data was col-
lected over the wavelengths 214–400 nm.
Chromatography was performed using a WATERS Prominence instrument (Waters MS Technologies, 
Manchester, UK) equipped with a 100 × 3.0 mm Symmetry C18, 3.5 μm column (Sunfire, Waters Corp, Milford, 
USA). The gradient elution mobile phase comprised of ACN (A) and 1 mM aqueous sodium acetate (B) mixture 
was delivered at a flow rate of 0.25 ml/min. The gradient was controlled as follows: 0–3.0 min, 20% A, 3.0–6.0 min, 
linear increase to 80% A, 6.0–9.0 min, 80% A, 9.0–12.0 min, linear decrease to 20% A. The column temperature 
was maintained at 40 °C and the autosampler was thermostatted at 4 °C. A 10.0 μL aliquot was injected into the 
LC/TOF MS system, and the total analytical run time was 12.0 min.
Mass spectrometry was performed on a Micromass LCT Premier system (Waters MS Technologies, 
Manchester, UK) operating in positive ion mode. The nebulization gas was set to 300 L/h at a temperature of 
350 °C, the cone gas was 10 L/min and the source temperature was 80 °C. The capillary voltage and cone voltage 
Short Incubation Regime (4 h pulsed exposure) Long Incubation Regime (72 h continuous exposure)
Cell lines Free PXT PCVPTX fP-PCVPTX
fP-PCVPTX with 
free folate Free PXT PCVPTX fP-PCVPTX
fP-PCVPTX 
with free folate
SKOV-3 3.79 ± 0.31 8.68 ± 0.88 2.42 ± 0.29 5.87 ± 0.56 0.30 ± 0.03 0.94 ± 0.11 0.43 ± 0.04 0.62 ± 0.05
A549 2.25 ± 0.19 8.73 ± 0.91 7.88 ± 0.82 6.42 ± 0.55 0.16 ± 0.02 0.49 ± 0.04 0.40 ± 0.05 0.47 ± 0.04
Table 1. Half-maximal inhibitory concentration (IC50) (μM, mean ± SD, n = 3) values of free PTX, 
PCVPTX, and fP-PCVPTX against SKOV-3 and A549 cell lines.
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were 3000 V and 60 V, respectively. The LCT-Premier was operated in the W optics mode with 12 000 resolution 
using the dynamic range extension (DRE). Data acquisition rate was set to 0.1 s, with 0.1 s interscan delay. All 
analyses were acquired using the lock spray to ensure accuracy and reproducibility; leucine-enkephalin was used 
as the lock mass (m/z 556.2771) at a concentration of 50 fmol/μL and flow rate of 5 μL/min. Data were collected in 
the centroid mode, with the lock spray frequency set at 5 s, and data were averaged over 10 scans.
Zeta potential and dynamic light scattering (DLS) measurements were performed on a Zetasizer Nano ZS 
(Marvern Instruments, Malvern, UK) with a He-Ne laser (633 nm) using a non-invasive backscatter method 
(detection at 173° scattering angle). Correlation data were fitted, using the method of cumulants, to the loga-
rithm of the correlation function, yielding the diffusion coefficient, D. The hydrodynamic diameters (DH) of the 
PCVs were calculated using D and the Stokes− Einstein equation (DH = kBT/3π η D, where kB is the Boltzmann 
constant, T is the absolute temperature, and η is the solvent viscosity (η = 0.8872 cP for water). The polydispersity 
index (PDI) of vesicles (represented as 2c/b2, where b and c are first- and second-order coefficients, respectively, 
in a polynomial of a semilog correlation function) was calculated by the cumulants analysis. Size distribution of 
the vesicles was obtained by the non-negative least-squares (NNLS) analysis32. Unless noted otherwise, for DLS 
measurements all samples were dispersed in 10 mM HEPES solution (pH 7.4, 150 mM NaCl). The data reported 
represent an average of ten measurements with twenty scans each.
Preparation of azide-Modified, Paclitaxel-loaded phosphonated Calix[4]arene Vesicles 
(PCVPTX). Paclitaxel-loaded p-phosphonated calix[4]arene vesicles were prepared using a modified literature 
procedure25. To a cylindrical glass vial (15 mm × 45 mm) was added P4C6 (26.41 μmol), P3C6N3 (0.26 μmol, 
1 mol % of the total P4C6), and paclitaxel (5.85 μmol) followed by chloroform (20 mL), affording a colorless solu-
tion. After vortexing (Heidolph Reax Top, John Morris Scientific Pty Ltd, Germany) 30 s, the solvent was removed 
by passing a stream of nitrogen over the solution while the vial was warmed in a 50 °C water bath. The resulting 
dry film was further dried under vacuum on a Schlenk line for one hour. Next, the dry lipid films were hydrated 
in 300 mM aqueous ammonium sulfate solution (500 μL) followed by vigorous probe sonication (2 min at 80% 
amplitude on Vibra cell Model VCX130, Sonics and Materials Inc, Australia) to form a dispersion of vesicles. 
The resulting PCVPTX solution was purified by Sephadex G-50 (10 mL) gel-filtration chromatography that was 
pre-equilibrated with HEPES buffer (20 mM; [NaCl] = 150 mM, pH 7.4) and then was further used directly in the 
conjugation with azide-PEG-folate (see below).
The loading of the PTX was determined by breaking up the PTX-loaded vesicles using a modified literature pro-
cedure25. The PTX-loaded vesicles involved vortex-mixing 500 μl of each solution with 2.5 ml of ACN for 5 min, fol-
lowed by centrifugation at 4820 g (5418 centrifuge, Eppendorf) for 10 min. The supernatant was transferred into glass 
autosampler vials and a 10 μl aliquot sample was injected into the LC/TOF MS system for analysis. Mean hydrody-
namic diameter (DH) of 139 ± 16 nm was determined by DLS measurements (Fig. 2). The resulting alkyne-modified, 
PTX-loaded PCV (PCVPTX) can then be used directly in conjugation with azide-PEG-folate (see below).
The paclitaxel loading in the PCV was quantified by LC-TOF/MS using an adapted literature method25. Under 
set electrospray ionization conditions, paclitaxel was predominantly the protonated fragment [M+ Na]+), and the 
MS parameters were optimized to maximize the response for the production of m/z 876.3224. The standard curve 
for paclitaxel was y = 255.21x + 62.18 (R2 = 0.999). The percent drug loading efficiency (DL) was calculated from 
the mass of paclitaxel in PCV (mp) and the total mass of paclitaxel loaded PCV using equation 2; Encapsulation 
efficiency (EE) was calculated from the mass of paclitaxel in PCV (mp) and the total mass of feeding paclitaxel 
(mfeeding paclitaxel) using equation 3.
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The loading efficiency (DL) and encapsulation efficiency (EE) were determined from three separately prepared 
vesicles suspensions, and was expressed as the mean ± standard deviation (Figure 3).
PTX-Release Assay under Various pH Conditions. The release rate of paclitaxel from PCVPTX was 
investigated using dialysis bags at pH 5.5 and 7.4. Here 10 mg PCVPTX was placed into a dialysis bag (Spectrum 
Laboratories, Inc., Rancho Dominguez, CA, cut off molecular weight of 3500 Da) containing PBS (1000 ml) buff-
ered to pH 5.5 or 7.4 with 1% Tween 80 and 0.5% FBS at 37.5 °C. At specific intervals the release medium which 
the dialysis bag was immersed in was sampled (5 mL) for analysis by the above mentioned LC/TOF MS method.
Conjugation of Azide-PEG-folate Ligand to Alkyne-Modified PCVPTX by Click Chemistry 
(Preparation of fP-PCVPTX). To a solution containing the alkyne-modified PCVPTX (570 μL of a 2.169 mM 
solution), azide-PEG folate ligand (24.72 μmol, 1 mol % of the total P4C6), CuSO4·5H2O (2 mM), and a freshly 
prepared aqueous solution of sodium ascorbate (1.2 mg in 300 μL of water, 6.18 μmol) was added and the reaction 
mixture was stirred at room temperature for 12 h. The resulting folate-conjugated PCVPTX solution was puri-
fied by Sephadex G-50 (10 mL) gel-filtration chromatography which was pre-equilibrated with HEPES buffer 
(20 mM; [NaCl] = 150 mM, pH 7.4). To determine the final concentration of PTX in the as-prepared fP-PCVPTX, 
a small amount of this solution was first broken up by vortex-mixing 500 μl of each solution with 2.5 mL of ACN 
for 5 min, followed by centrifugation at 4820 g (5418 centrifuge, Eppendorf) for 10 min. The supernatant was 
transferred into glass autosampler vials and a 10 μl aliquot sample was injected into the LC/TOF MS system for 
analysis.
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To determine the yield of the “click” reaction, the same conjugation described above was carried out with 
alkyne-modified empty PCVs (vide supra). This was necessary to avoid the overlapping UV− vis absorbances 
between PTX and folate in fP-PCVPTX. The yield of the conjugation with folate was determined by quantitative 
UV-vis spectroscopy based on the extinction coefficient (ϵ ) of folic acid (λ max = 291 nm, Fig. S2 in Supporting 
Information).
Preparation of PCVFITC and fP-PCVFITC. For detection by flow cytometry and confocal microscopy, 5 μmol 
FITC was incorporated in the place of PTX, as described above, to obtain PCVFITC and fP-PCVFITC. PCVFITC and 
fP-PCVFITC are very stable (less than 5% FITC leaking from vesicles) in room temperature and neutral pH for 
24 hours whereupon multiple dilutions applied (up to 1,000 times).
Cell Culture Studies
a. Medium. Trypsin solution (0.25%, containing EDTA) was purchased from Sigma-Aldrich (Castle Hill, 
AU). Ham’s F-12K (Kaighn’s) Medium, McCoy’s 5A (modified) Medium, Penicillin-Streptomycin, DAPI Nucleic 
Acid Stain, and phosphate-buffered saline (PBS, 1× without calcium and magnesium) solutions were purchased 
from Invitrogen (San Diego, CA).
b. Cell Lines. Human ovarian adenocarcinoma (SKOV-3), known to overexpress the folate receptor was 
supplied from the American Type Culture Collection (ATCC). Human lung alveolar adenocarcinoma (A549) 
was used as the control cell line and was supplied from the ATCC. SKOV-3 cells were continuously cultured in 
folate-free McCoy’s 5A (modified) Medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum 
(FBS) and 0.5% (v/v) Penicillin-Streptomycin solution at 37 °C in a humidified atmosphere containing 5% CO2. 
A549 cells were continuously cultured in Ham’s F-12K (Kaighn’s) Medium supplemented with 10% (v/v) FBS, 
1% (v/v) Penicillin-Streptomycin solution at 37 °C in a humidified atmosphere containing 5% CO2 (Figs 6 and 7).
Confocal Laser Scanning Microscopy (CLSM) and Flow Cytometry Study. SKOV-3 and A549 
cells were planted in 12-well plate containing a sterilized glass coverslip (2 mL/well, 2.5 × 106 cells/mL) for 24 h 
at 37 °C and 5% CO2 before each experiment. Each cell was incubated with the appropriate FITC formulation 
in cell culture medium (500 μL) with or without free folate for 8 h at 37 °C and 5% CO2. After the removal of 
FITC-containing medium, the cell layers were washed with cold PBS (40 × 2 mL). Then 300 nM DAPI staining 
solution was added to the coverslip and made sure all the cells were completely covered. After incubation for 
3 minutes, the samples were rinsed three times with PBS. Next, the coverslips were placed on slides (Livingstone 
Ltd, NSW, AU) coated with PBS (50 μL). CLSM images were observed with inverted confocal laser scanning 
microscope (Leica TCS SP2 multiphoton confocal microscope) with excitation at 488 nm. A NA1.4 oil immersion 
objective was used. The rest of the cells were digested using 0.25% Trypsin. After centrifugation, the resulting 
pellet was redispersed in pH 7.4 PBS for flow cytometry analysation (Figure 8).
Cytotoxicity Assays. The cells were seeded in 6-well plates (500 μL/well) with a concentration of 
2.5 × 106 cells/mL in folate-free medium and were incubated to grow for 24 h. The media in the wells were 
replaced with the preprepared growth media containing the appropriate drug formulation (200 μL of solution at 
the appropriate paclitaxel concentrations (0.01–900 μM). For exposure regime 1, the drug-treated cells were then 
further incubated for 4 h in a humidified atmosphere containing 5% CO2 at 37 °C, after which the drug-containing 
media were removed by aspiration. The remaining cell layers were washed with PBS buffer (2 × 250 μL) followed 
by replacement with fresh growth media (200 μL). The plates were then maintained in the incubator at 37 °C for 
a further 68 h. For exposure regime 2, the drug-treated cells were incubated for 72 h in a humidified atmosphere 
containing 5% CO2 at 37 °C, after which the cells were washed with PBS buffer (2 × 250 μL).
The total cells from cultures were differentially stained with Dead Cell Apoptosis Kit (Life Technologies, San 
Diego, CA) which contained two fluorescence dyes (Annexin V FITC and PI), allowing assessment of the viable, 
dead, and apoptotic cells. The number of viable cells was counted by a BD FACSCalibur flow cytometer and was 
plotted against the total PTX concentration. The data reported represent an average of three measurements from 
different batches. The dose-response curves shown in Fig. 8 were obtained by sigmoidal logistic fitting using 
Origin 8.5 and the half-maximal inhibitory concentration (IC50) values were determined on the basis of the fitted 
data.
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